Genomics and Precision Health Posts

Tracking the Scientific Literature on the Impact of Pharmacogenomics on Clinical Practice and Public Health

bar graph of Trends in pharmacogenomic implementation studies, 2012-2021

Pharmacogenomics (PGx) is an emerging field that investigates genetic differences in drug effectiveness and safety. PGx is an essential component of precision medicine  and seeks to provide the right medication for the right person at the right time. Advances in PGx promise to improve treatment of many diseases such as cancer and cardiovascular disease. In Read More >

Posted on by Sarina Abrishamcar, Emory University Rollins School of Public Health, W. David Dotson, and Muin J. Khoury, Office of Genomics and Precision Public Health, Centers for Disease Control and PreventionLeave a comment

Precision Public Health in Action: Enhancing models to predict risk of adverse treatment outcomes in people with hemophilia

hemophilia an data

In collaboration with the CDC Office of Advanced Molecular Detection, the Office of Genomics and Precision Public Health recently funded the National Center on Birth Defects and Developmental Disabilities (NCBDDD) to strengthen public health capacity by introducing elements of human genomics into applied research on predicting inhibitor risk in people with hemophilia. Hemophilia refers to a group Read More >

Posted on by Christopher J. Bean, PhD and Amanda B. Payne, PhD MPH - National Center on Birth Defects and Developmental DisabilitiesLeave a commentTags

From Guthrie to Genomes: Expanding Bioinformatic Capabilities in Newborn Screening Programs

a newborn babies foot on sequencing with certain sequencing pointed to with a red arrow

Through a funding opportunity from CDC’s Office of Genomics and Precision Public Health in collaboration with the Office of Advanced Molecular Detection, CDC’s Newborn Screening and Molecular Biology Branch will conduct a two-year project to develop a streamlined national newborn screening (NBS) bioinformatics pipeline to help in expanding the use and utility of gene and Read More >

Posted on by Amy Gaviglio and Carla Cuthbert, Division Of Laboratory Sciences, Centers for Disease Control and PreventionLeave a commentTags

Assessing Pharmacogenetic Variation in the United States to Enhance Health Equity of Pharmacogenetic Testing

DNA in a pill on top of a map from the US

CDC’s Genetic Testing Reference Material program (GeT-RM), in the Division of Laboratory Systems will conduct a 2-year project to test 5000 DNA samples from the population-based National Health and Nutrition Examination Survey (NHANES) to determine the allele frequencies of 970 unique haplotypes in 150 pharmacogenes selected because they have high clinical annotation levels of evidence Read More >

Posted on by Lisa Kalman, PhD. Division of Laboratory Systems, Centers for Disease Control and Prevention, Atlanta, GeorgiaLeave a commentTags

Using Immunogenetics in the Fight Against Ebola Virus Disease

DNA and Ebola

CDC’s Viral Special Pathogens Branch focuses on viruses causing hemorrhagic fevers and requiring the highest levels of biological containment. Within VSPB, the Molecular Pathogenesis and Therapeutics Team conducts basic and applied research to understand how these viruses interact with our bodies to cause disease, and how this knowledge can be used to develop and evaluate Read More >

Posted on by Markus Kainulainen, Division of High Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GeorgiaLeave a commentTags ,

Epigenetics: An Emerging Tool for Health Equity Science

people holding hands below DNA

A recent review provides recommendations to improve the scientific investigation of the associations between epigenetic markers, socioeconomic status, and adverse health outcomes. Health equity means that everyone has the opportunity to be as healthy as possible. Health equity science studies the association between social determinants of health (SDOH) and adverse health outcomes. SDOH refer to Read More >

Posted on by Emily Drzymalla, Marta Gwinn, Muin J. Khoury, Office of Genomics and Precision Public Health, Centers for Disease Control and PreventionLeave a commentTags

Artificial Intelligence in Medicine and Public Health: Prospects and Challenges Beyond the Pandemic

a woman pointing at DNA wiith AI in the background

Though still in its infancy as a field, artificial intelligence (AI) is poised to transform the practice of medicine and the delivery of healthcare. Powered by breakthroughs in machine learning (ML) algorithms, enhanced computing power, and increasing data volume and storage capacity, AI has made noteworthy advances over the past decade across many medical subspecialties. Read More >

Posted on by Danielle Rasooly, Muin J. Khoury, Office of Genomics and Precision Public Health, Centers for Disease Control and Prevention, Atlanta, GeorgiaLeave a commentTags

Rare Disease Day 2022: The Evolving Impact of Genomics and Precision Health

Rare Disease Day 2022 with a ribbon and a map of the world

In celebration of Rare Disease Day 2022, we reprint excerpts of four previous blogs. Rare Diseases, Genomics and Public Health: An Expanding Intersection (February 17, 2016) Rare Disease Day is celebrated on the last day of February each year. On that day, millions of patients and their families around the world share their stories in order Read More >

Posted on by Muin J. Khoury, Office of Genomics and Precision Public Health, Centers for Disease Control and Prevention, Atlanta, GeorgiaLeave a commentTags

Using Pharmacogenetics to Enhance Tuberculosis (TB) Treatment

a person pointing at different icons with tuberculosis in the background

Through a funding opportunity from CDC’s Office of Genomics and Precision Public Health in collaboration with the CDC Office of Advanced Molecular Detection, CDC’s Division of Tuberculosis Elimination will conduct a 2-year project to assess relationships between pharmacogenetics (PG), TB drug exposure, relevant treatment outcomes, and safety. Researchers will use information collected in an international phase Read More >

Posted on by Meredith Moore, MPH, Bria Marlowe, MPH, CHES, ORISE Fellow, Carla Jeffries, JD, MPH, Wendy Carr, PhD, Ekaterina Kurbatova, MD, PhD, MPH. Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, GeorgiaLeave a commentTags

Precision Public Health in Action: New CDC Pilot Projects Integrate Human Genomics into Public Health Surveillance and Applied Research

a magnifying glass looking at a globe with DNA

In collaboration with the CDC Office of Advanced Molecular Detection, we recently launched a new, five-year initiative to strengthen public health capacity by introducing elements of human genomics into both public health surveillance and applied research. We report here on the successful launch of one of the initiative’s components. The Office of Genomics and Precision Public Read More >

Posted on by Mindy Clyne, W. David Dotson, Muin J. Khoury, Office of Genomics and Precision Public Health, Centers for Disease Control and Prevention, Atlanta, GeorgiaLeave a comment